We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
126
ADMA Biologics
ADMA
$2.03B
$335K 0.01%
16,900
– –
EXEL icon
127
Exelixis
EXEL
$14B
$314K 0.01%
+8,500
New +$303K
ASND icon
128
Ascendis Pharma A/S
ASND
$16.5B
$296K 0.01%
1,900
-600
-24% -$85.7K
OCS icon
129
Oculis Holding
OCS
$708M
$268K 0.01%
14,100
+4,100
+41% +$84K
MLYS icon
130
Mineralys Therapeutics
MLYS
$2.35B
$262K 0.01%
16,499
– –
QURE icon
131
uniQure
QURE
$2.73B
$239K 0.01%
22,500
– –
ACLX
132
DELISTED
Arcellx
ACLX
$197K ﹤0.01%
3,000
– –
PTCT icon
133
PTC Therapeutics
PTCT
$6.47B
$194K ﹤0.01%
3,800
– –
GRMN
134
Garmin
GRMN
$47.2B
$185K ﹤0.01%
850
-200
-19% -$43.2K
BIDU icon
135
Baidu
BIDU
$37.4B
$184K ﹤0.01%
2,000
– –
AMZN icon
136
Amazon
AMZN
$2.69T
$171K ﹤0.01%
+900
New +$195K
GOOGL icon
137
Alphabet (Google) Class A
GOOGL
$4.3T
$170K ﹤0.01%
+1,100
New +$199K
CYTK icon
138
Cytokinetics
CYTK
$10.7B
$150K ﹤0.01%
3,741
-7,200
-66% -$331K
MLTX icon
139
MoonLake Immunotherapeutics
MLTX
$1.59B
$117K ﹤0.01%
3,000
-1,400
-32% -$60.3K
BRBR icon
140
BellRing Brands
BRBR
$1.41B
$104K ﹤0.01%
+1,400
New +$103K
A icon
141
Agilent Technologies
A
$36.8B
$94.3K ﹤0.01%
806
– –
ORCL icon
142
Oracle
ORCL
$350B
$91.4K ﹤0.01%
654
– –
NVDA icon
143
NVIDIA
NVDA
$4.92T
$81.4K ﹤0.01%
751
– –
MSFT icon
144
Microsoft
MSFT
$2.99T
$76.2K ﹤0.01%
203
– –
QCOM icon
145
Qualcomm
QCOM
$180B
$68.7K ﹤0.01%
447
– –
BIIB icon
146
Biogen
BIIB
$29.5B
$55K ﹤0.01%
402
-2,250
-85% -$322K
MTD icon
147
Mettler-Toledo International
MTD
$25.7B
$49.6K ﹤0.01%
42
– –
TEM
148
Tempus AI
TEM
$8.69B
$11.4K ﹤0.01%
237
– –
AMRX icon
149
Amneal Pharmaceuticals
AMRX
$5.59B
– –
-100,414
Closed -$795K
ARVN icon
150
Arvinas
ARVN
$517M
– –
-2,389,600
Closed -$45.8M
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.